Connect with us

Hi, what are you looking for?

Investing

Cardiex Completes HEARTsense Wearable Study and Secures US Wearable Patent

CARDIEX Limited (ASX:CDX) (CARDIEX, the Company) is pleased to announce the successful completion of two significant milestones in the commercialization of its wearable biomarker technology.

Successful Completion of HEARTsense Wearable Study.

The Company has successfully completed its primary study validating the use of its SphygmoCor® biomarker technology in wearables by way of a PPG (Photoplethysmogram) sensor (the “HEARTsense Study”). The objective of the HEARTsense Study was to successfully demonstrate the ability to extract vascular biomarkers from a wearable PPG sensor that could previously only be achieved with the Company’s “gold standard” XCEL biometric monitor, and the soon to be released Pulse biometric monitor.

The XCEL biometric monitor is the market leader in measuring central non-invasive vascular biomarkers and is used by all top 20 US hospitals, global pharmaceutical companies (47 clinical trials), research (2300+ research papers), and in specialist clinical practices. The HEARTsense Study showed that that same proprietary XCEL technology can now be ported into a wearable device in a format compatible with commonly used wearable sensor devices.

Completion of the HEARTsense study is also a key step for the Company as it prepares to lodge its FDA submission for clearance of its CONNEQT Band wearable technology in Q1 FY2025, as well as being a key step towards commercialization.

Commenting on the results of the HEARTsense Study, Cardiex CEO Craig Cooper stated:

“This is a significant achievement for the Company as well as being a game changer for the medical technology industry. This is the first time that medical-grade measurements of arterial health, arterial stiffness, and vascular age have been made by way of a finger-based PPG sensor in a wearable; opening the path to commercialization in a number of device formats.

Our technology strategy has always been to produce products that can be deployed in medical and consumer settings for clinics, in the home, and when on-the-go. Importantly, it’s our focus on medical-grade wearable solutions which distinguishes us from other companies. The HEARTsense Study is a strong validation of that strategy as well as being a key step towards FDA clearance of our CONNEQT Band wearable technology.”

Results of the HEARTsense Study are in the process of being submitted for publication in leading peer-reviewed medical and scientific journals.

Click here for the full ASX Release

This post appeared first on investingnews.com

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.






    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Latest News

    North Korea may be known as the hermit kingdom, but the isolated nation could be edging toward opening its borders to small numbers of...

    Latest News

    Evacuations are underway across Hawaii’s Big Island and Maui as passing Hurricane Dora helps fuel wildfires that have damaged structures, prompted rescues and spurred...

    Editor's Pick

    One of the perks of being speaker of the House — or at least, one of the characteristics of it — is that you...

    Latest News

    Former world No. 1 Caroline Wozniacki won her first competitive tennis match in three-and-a-half years on Tuesday, defeating Australian Kimberly Birrell 6-2 6-2 at...

    Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2023 balanceandcharge.com